不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Medtronic 发表治疗主动脉瓣疾病器材的研究报告

Medtronic 发表治疗主动脉瓣疾病器材的研究报告

Medtronic2011年2月19日 16:53 点击:1443

美国美敦力公司(Medtronic, Inc.)

MEdtronic发表独立研究报告,病人接受Medtronic CoreValve)系统治疗主动脉瓣疾病(AVD),临床上初期与持续有利於病人。这篇报告讨论最大规模的CoreValve临床研究,在2007年器材问世後,有663位AVD病人在14所义大利中新接受治疗,这些老人病患年龄中间值为81岁。

Medtronic Media Contacts:
, Investor Relations, 763-505-2696
, Public Relations, 763-526-3676
 

CoreValve Italian Registry Results Demonstrate Clinical Benefits in a Real-World Patient Population


 

MINNEAPOLISFebruary 18, 2011 – Medtronic, Inc. (NYSE: MDT) today issued a statement on results from an independent study published online in the journal Circulation, which confirmed both early and sustained clinical benefits for patients receiving the Medtronic CoreValve® System for the treatment of aortic valve disease. The article, “Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis,”  discusses the largest CoreValve clinical study to date, with 663 consecutive aortic stenosis patients (mean age of 81 years) treated at 14 Italian centers beginning immediately after device commercialization in 2007. The article shows that patients receiving CoreValve have high rates of procedural success (98 percent), low rates of adverse events (2.1 percent) and substantial improvements of cardiac function.

The Medtronic CoreValve System is a minimally invasive, non-surgical treatment option for patients with requiring aortic valve replacement who are considered at high risk for surgery; CoreValve is delivered via transcatheter aortic valve implantation (TAVI) rather than open-heart surgery. The CoreValve system received CE (Conformité Européenne) Mark in March 2007 and has been implanted in more than 12,000 patients worldwide in 42 countries outside the United States. In the U.S., the CoreValve System is being evaluated in a U.S. Pivotal Clinical Trial.

不用本金就能赚钱的方法“The positive results of our TAVI experience are encouraging and demonstrate positive clinical outcomes for a group of patients with few treatment options,” said Corrado Tamburino, M.D., Ph.D., of Ferrarotto Hospital in Catania, Italy and principal investigator of the study. “Our findings demonstrate that a large majority of patients were treated successfully with CoreValve and experience improvements in heart function. This real-life registry gives further credence to this new therapy approach.”

In this study, procedural success was 98 percent and intraprocedural mortality was 0.9 percent. Cumulative incidences of mortality were 5.4 percent at 30 days, 12.2 percent at 6 months, and 15 percent at one year. Additionally, the study reported low rates of permanent pacemaker implantation (16.6 percent at 2-weeks and 17.4 percent at 30-days).There also was substantial and sustained improvement in patients’ health status, with 71.5 percent of patients in NYHA class III and IV  before the implant achieving class I or II  after the procedure.

The Italian Registry data also evaluated the incidence and predictors of early (30 days) and late (30 days to 1 year) mortality after TAVI. The authors concluded that while early mortality was strongly associated with procedural complications, late mortality was associated with co-morbidities (such as a prior stroke, a prior episode of acute pulmonary edema, or chronic kidney disease) and that pacemaker implant was not a factor.

“We welcome the robust findings from the Italian Registry, which substantially enhance the strong body of clinical evidence supporting the sustained clinical benefits of CoreValve in real-life clinical application,” said John Liddicoat, M.D., vice president and general manager of the Structural Heart division at Medtronic. “We are committed to supporting clinical evaluation of the CoreValve system to offer patients with severe aortic stenosis the safest and most adequate technique for treating this disease.”

About CoreValve
Approximately 300,000 people worldwide have been diagnosed with this severe aortic stenosis, and approximately one-third of these patients are deemed at too high a risk for open-heart surgery.i The Medtronic CoreValve U.S. Pivotal Clinical Trial began in late 2010 and will enroll more than 1,300 patients at 40 U.S. clinical sites which are identified on . Additional information for patients and referring physicians can be found at . CoreValve is not yet available in the U.S. for commercial sale or use.

About Medtronic
Medtronic, Inc. (), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

– end –

(来源: Medtronic )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图